Therapeutic-interchange program for oral histamine H2-receptor antagonists.
A therapeutic-interchange (TI) program for oral histamine H2-receptor antagonists at a hospital is described. In 1992 the pharmacy and therapeutics committee at a large teaching hospital accepted cimetidine as the preferred oral H2 antagonist. However, the program to promote cimetidine met with little success. The manufacturer of nizatidine then offered the hospital that drug at a reduced cost relative to all other members of the drug class. The committee recommended including nizatidine on the formulary; implementing a TI program so that when an order for an oral H2 antagonist was written nizatidine would be dispensed; deleting cimetidine and ranitidine tablets from the formulary; and retaining cimetidine and ranitidine oral liquid and i.v. formulations. The program was approved by the medical executive committee and was implemented in August 1994. Extensive efforts to inform the pharmacy, medical, and nursing staffs about the program were undertaken, and the pharmacy established mechanisms for monitoring compliance. Two months into the program, 97% of eligible patients were receiving nizatidine. Actual cost savings in the first four months exceeded $40,000. In July 1997 the same program was applied to famotidine, which had replaced nizatidine as the most cost-effective H2 antagonist. A successful TI program for oral H2 antagonists was achieved by gaining physician support for the program, educating providers, monitoring compliance, and responding to changes in drug costs.
Chase
S L
SL
Drug Use Policy and Clinical Services, Thomas Jefferson University Hospital (TJUH), Philadelphia, PA 19107-5098, USA.
Peterson
A M
AM
Wordell
C J
CJ
D002927:Cimetidine / Q000191:economics* / Q000627:therapeutic use; D004363:Drug Utilization; D006635:Histamine H2 Antagonists / Q000191:economics* / Q000627:therapeutic use; D006746:Hospital Bed Capacity, 500 and over; D006784:Hospitals, Teaching; D006801:Humans; D016567:Nizatidine / Q000191:economics* / Q000627:therapeutic use; D010414:Pennsylvania; D010607:Pharmacy Service, Hospital / Q000191:economics / Q000458:organization & administration*
D006635:Histamine H2 Antagonists; D002927:Cimetidine; D016567:Nizatidine